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What is the most effective 
local anesthesia for transrectal 
ultrasonography-guided biopsy of 
the prostate? A systematic review 
and network meta-analysis of 47 
randomized clinical trials
Do Kyung Kim1, Joo Yong Lee  2, Jae Hung Jung3, Yoon Soo Hah  1, Kyo Chul Koo1, 
Kwang Suk Lee1, Byung Ha Chung  1 & Kang Su Cho1
We aimed to compare the effectiveness of various local anesthetic methods for controlling prostate 
biopsy (PBx) related pain using network meta-analysis. Literature searches were performed on 
PubMed/Medline, Embase, and Cochrane Library up to March 2018. Forty-seven randomized controlled 
trials, in which the effectiveness of PBx-related pain was investigated using a visual analogue scale after 
various local anesthetic methods, were included. The local anesthetic methods included intraprostatic 
local anesthesia (IPLA), intrarectal local anesthesia (IRLA), intravenous sedation (IVS), periprostatic 
nerve block (PNB), pelvic plexus block (PPB), and spinal anesthesia (SPA). Eight pairwise meta-analyses 
and network meta-analyses with 21 comparisons were performed. All modalities, except single use 
of IPLA and IRLA, were more effective than placebo. Our results demonstrate that PNB + IVS (rank 
1) and SPA (rank 2) were the most effective methods for pain control. The followings are in order of 
ppB + IRLA, PNB + IPLA, PPB, PNB + IRLA, IVS, and PNB. In conclusion, the most effective way 
to alleviate PBx-related pain appears to be PNB + IVS and SPA. However, a potential increase in 
medical cost and additional risk of morbidities should be considered. In the current outpatient setting, 
ppB + IRLA, PNB + IPLA, PPB, PNB + IRLA, and PNB methods are potentially more acceptable options.
The introduction of transrectal ultrasonography (TRUS)-guided prostate biopsy (PBx) in 1989 was a significant 
development in diagnostic methodology for detection of prostate cancer (PCa). This new method quickly became 
the gold standard for the detection of PCa and remains the method of choice to the present day1. Although many 
patients can tolerate PBx the procedure can cause severe pain2. A random sampling method is used in PBx, so 
10 or more core biopsy recommended to increase the detection rate of PCa3. However, as the number of core 
increases to achieve better detection rate, the patient experiences more pain. Severe pain can cause the patient to 
move during the procedure, which can increase the rate of complications and decrease the number of core that 
can be taken. These factors can potentially decrease accuracy of the final diagnosis4,5. These pitfalls highlight the 
importance of performing PBx with optimal local anesthesia for patient safety and accurate diagnosis4.
Various types of local anesthesia have been used for TRUS-guided PBx, including the most common methods 
of intrarectal local anesthesia (IRLA) and periprostatic nerve block (PNB)6. IRLA has been recommended as a 
non-invasive alternative to relieve pain during PBx7. Periprostatic injection of lidocaine into the neurovascular 
bundles markedly decreases the discomfort associated with PBx8. In addition to IRLA and PNB, intraprostatic 
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local anesthesia (IPLA), spinal anesthesia (SPA; low dose spinal anesthesia or caudal block), intravenous sedation 
(IVS), and pelvic plexus block (PPB) are used for pain control during PBx. There are many randomized con-
trol trials (RCTs) that compare the effects of these anesthetic methods, alone or in combination, with placebo. 
However, the question of which method is the most effective way to control pain during PBx remains unanswered.
The purpose of the present study was to compare the effectiveness of various local anesthetic methods for con-
trolling PBx-related pain to determine the best approach. To accomplish this, we performed a systematic review 
of the published literature and network meta-analysis of the available data.
Results
Systematic review process. A summary of the analysis results is shown as a PRISMA flow diagram, repre-
senting a visual flowchart, in Fig. 1. A total of 1842 articles were found in initial database searches. Of these, 982 
articles remained after removing duplicates. After excluding non-English articles, editorials, letters, reviews, case 
reports, and articles not related to this study by reviewing the titles and abstracts of all available literature, 134 
articles remained. Next, a review of full-text articles was performed to evaluate whether they met the inclusion 
criteria. A total of 47 RCTs1–5,9–50 with a total of 5,758 patients were finally included in this study. The character-
istics of included studies are displayed in Table 1. All articles were prospective RCTs, and VAS was used to assess 
pain in all trials. The PNB injection site was the base, with or without apex. The number of PBx core ranged from 
6 to 14 across all studies.
Pairwise meta-analysis. IRLA vs. Placebo. Eight studies showed that IRLA demonstrated no statistically 
significant pain relief compared to placebo (MD: −0.32, 95% CI: −0.72 to 0.09, P = 0.13, Fig. 2A). Heterogeneity 
among the included studies was observed (P = 0.001; I2 = 70%).
PNB vs. IRLA. Fourteen studies showed that PNB was significantly lower compared to that of IRLA (MD: 
−1.61, 95% CI: −2.08 to −1.15, P < 0.00001, Fig. 2B). Heterogeneity among the included studies was observed 
(P < 0.00001; I2 = 88%).
PNB vs. Placebo. Ten studies showed that PNB significantly reduced pain compared with placebo (MD: 
−2.04, 95% CI: −2.77 to −1.31, P < 0.00001, Fig. 2C). Heterogeneity among the included studies was observed 
(P < 0.00001; I2 = 90%).
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analysis flowchart RCT: randomized 
controlled trial.
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First
Author,
year
Study
design
Treatment arms
(number of patients) Anesthetics
Number
of prostatic
core
Injection Site 
of PNB
Pain 
Scale
Adamakis, 20049 RCT P (40); IRLA (78);PNB (80)
PNB: 2% lidocaine (5 mL)
IRLA: Lidocaine–prilocaine cream 
(10 mL)
10 Base VAS
Akpınar, 200910 RCT PNB (40); PPB (40) PNB: 2% lidocaine (2 mL)PPB: 2% lidocaine (2 mL) 12 Base VAS
Aktoz, 200911 RCT PNB (30); IRLA (30); PNB + IRLA (30)
PNB: 0.75% levobupivacaine 
(3.3 mL)
IRLA: Diclofenac sodium 
suppository (50 mg)
10 Base + Apex VAS
Alavi, 200112 RCT PNB(75); IRLA(75) PNB: 1% lidocaine (10 mL)IRLA: 2% lidocaine gel (10 mL) 6–14 Base VAS
Anastasi, 201613 RCT PNB (50); IRLA (50) PNB: 1% lidocaine (10 mL)IRLA: 1% lidocaine gel (5 mL) 12 NA VAS
Atta, 201814 RCT PNB (100); IVS (100); PNB + IVS (100)
PNB: 1% lidocaine (10 mL)
IVS: diazepam (5 mg) 10 Base VAS
Bingqian, 200915 RCT PNB (100);PNB + IPLA (100)
PNB: 1% lidocaine (10 mL)
IPLA: 1% lidocaine (10 mL) 14 Base VAS
Cam, 200816 RCT PNB (100);PNB + IPLA (100)
PNB: 2% lidocaine (5 mL)
IPLA: 2% lidocaine (5 mL) 12 Base VAS
Cantiello, 201217 RCT PPB + IRLA (90);PNB + IRLA (90)
PPB and PNB: 1% 
lidocaine + 0.75% naropine 
(2.5 mL)
IRLA: 1.5% lidocaine gel 
(10 mL) + 0.3% nifedipine cream
12 Base VAS
Cevik, 200218 RCT P (50); IRLA (50) IRLA: 2% lidocaine gel (20 mL) >8 VAS
Chang, 200119 RCT P (52); IRLA(56) IRLA: 2% lidocaine gel (10 mL) >8 VAS
Galosi, 20055 RCT P(19); IRLA(60) IRLA: EMLA cream (5mL) and 2.5% lidocaine gel (10 mL) 6–7 VAS
Giannarini, 20094 RCT PNB (68); IRLA (67); PNB + IRLA (68)
PNB: 1% lidocaine (10 mL)
IRLA: Lidocaine–prilocaine cream 
(5 mL)
10 Base VAS
Goluza, 201020 RCT P (80); IRLA(80) IRLA: Lidocaine suppository (60 mL) 12 VAS
Gurubuz, 201021 RCT PNB (25); IRLA (25)
PNB: 1% lidocaine (10 mL)
IRLA: Lidocaine–prilocaine cream 
(5mL)
10 Base + Apex VAS
Hiros, 201022 RCT PNB (30); IRLA (30) PNB: 1% lidocaine (10 mL)IRLA: Voltaren Suppository 10 Base + Apex VAS
Inal, 200423 RCT P (30); PNB (30) PNB: 1% lidocaine 6–12 Base VAS
Ingber, 20103 RCT P (49); PNB (49) PNB: 1% lidocaine (5mL) 10 Base VAS
Izoi, 20122 RCT PNB (25); IRLA (25) PNB: 2% lidocaine (5mL)IRLA: 2% lidocaine gel (10 mL) 12 Base VAS
Jindal, 201424 RCT IRLA (46); PPB + IRLA (47); PNB + IRLA(46)
PPB and PNB: 2% lidocaine (5mL)
IRLA: 2% lidocaine gel (10 mL) 12 Base VAS
Kravchick, 200425 RCT PNB (27); IRLA (28) PNB: 1% lidocaine (5mL)IRLA: 2% lidocaine gel (10 mL) 6 NA VAS
Kucur, 20151 RCT PNB + IRLA (50); SPA (50)
PNB: 2% lidocaine (5mL)
IRLA: 2% lidocaine gel (10 mL)
SPA: 0.5% bupivacaine (0.3mL)
14 Base VAS
Kumar, 201326 RCT PNB (50); PNB + IPLA (50)
PNB: 1% lidocaine (10 mL)
IPLA: 1% lidocaine (5 mL) 12 Base VAS
Lee, 200428 RCT PNB (35); IRLA (37) PNB: 1% lidocaine (5mL)IRLA: 2% lidocaine gel (10 mL) 8–12 Base VAS
Lee, 200727 RCT PNB (49); IPLA (41);PNB + IPLA (62)
PNB: 1% lidocaine (2 mL)
IPLA: 1% lidocaine (2 mL) 12 Base VAS
Leung, 200629 RCT P (169); IRLA (169) IRLA: 2% lidocaine gel (10 mL) 10 VAS
Mallick, 200530 RCT PNB (176); IRLA (180) PNB: 1% lidocaine (10 mL)IRLA: 2% lidocaine gel (15 mL) 10 Base VAS
Mazdak, 201831 RCT
PNB + IRLA (36);
IVS (35);
SPA (35)
PNB: 2% lidocaine (5 mL)
IRLA: 2% lidocaine gel (10 mL)
IVS: midazolam (25 μg/kg), 
fentanyl (2 μg/kg),
and ketamine (1 mg/kg)
SPA: 0.5% bupivacaine (1.5mL)
12 Base VAS
Nambirajan, 200432 RCT P (48); PNB (48) PNB: 1% lidocaine (5 mL) 10 Base + Apex VAS
Noh, 201033 RCT PNB (38); PNB + IRLA (36)
PNB: 1% lidocaine (10 mL)
IRLA: Lidocaine–prilocaine cream 
(5 mL)
12 NA VAS
Continued
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PNB + IPLA vs. PNB. Five studies showed that PNB + IPLA significantly reduced pain compared with PNB 
(MD: −0.97, 95% CI: −1.33 to −0.60, P < 0.00001; Fig. 2D). Heterogeneity among the included studies was not 
observed (P = 0.001, I2 = 78%).
PNB + IRLA vs. IRLA. Four studies showed that PNB + IRLA significantly reduced pain compared with 
IRLA (MD: −1.75, 95% CI: −2.97 to −0.53, P = 0.005; Fig. 2E). Heterogeneity among the included studies was 
observed (P < 0.00001; I2 = 96%).
PNB + IRLA vs. PNB. Seven studies were included in the analysis that compared PNB + IRLA with PNB 
(Fig. 2F). Combined PNB + IRLA resulted in significantly lower VAS scores than PNB alone (MD: −0.61, 95% 
CI: −1.09 to −0.13, P = 0.01). Heterogeneity among the included studies was observed (P < 0.00001; I2 = 87%).
PPB + IRLA vs. PNB + IRLA. Two studies showed that PPB + IRLA significantly reduced pain compared with 
PNB + IRLA (MD: −1.09, 95% CI: −1.29 to −0.90, P < 0.00001; Fig. 2G). Heterogeneity among the included 
studies was not observed (P = 0.96; I2 = 0%).
SPA vs. PNB + IRLA. Three studies showed that although SPA seems to have reduced pain compared with 
PNB + IRLA, the result was not statistically significant (MD: −1.47, 95% CI: −2.73 to −0.21, P = 0.02; Fig. 2H). 
Heterogeneity among the included studies was observed (P < 0.00001; I2 = 97%).
Bayesian framework network meta-analysis. The network meta-analysis was performed with 47 stud-
ies. Eleven nodes (10 local anesthetic methods plus placebo) and 21 comparisons in the network plot of evidence 
are shown in Fig. 3. The width of each line is proportional to the number of trials comparing every pair of treat-
ments, and the size of every node is proportional to the number of randomized participants.
The network meta-analysis results are described in Fig. 4. Compared to placebo, PNB + IVS, SPA, PPB + IRLA, 
PNB + IPLA, PPB, PNB + IRLA, IVS, and PNB were significantly more effective on PBx-related pain control. 
Neither IPLA nor IRLA showed a significant difference in VAS compared to placebo. The relative effect plot 
First
Author,
year
Study
design
Treatment arms
(number of patients) Anesthetics
Number
of prostatic
core
Injection Site 
of PNB
Pain 
Scale
Obi, 201134 RCT PNB (25); SPA (25) PNB: 1% lidocaine (10 mL)SPA: 0.5% bupivacaine (0.5 mL) 6–8 Base + Apex VAS
Ozden, 200335 RCT P (25); PNB (25) PNB: 1% lidocaine (10 mL) 8 Base, Base + Apex VAS
Raber, 200537 RCT P (49); IRLA(48) IRLA: Lidocaine–prilocaine cream (5 mL) 12 VAS
Raber, 200836 RCT PNB (100);PNB + IRLA (100)
PNB: 2% lidocaine (10 mL)
IRLA: Lidocaine–prilocaine cream 
(5 mL)
14 Base VAS
Rodriguez, 200338 RCT PNB (53); IRLA (43) PNB: 1% lidocaine (10 mL)IRLA: 2% lidocaine gel (10 mL) 6–14 Apex VAS
Seckiner, 201139 RCT P (31); PNB (29) PNB: 2% lidocaine (5 mL) 7–8 Base VAS
Singh, 201240 RCT P (49); PNB (46);PNB + IPLA (47)
PNB: 1% lidocaine (10 mL)
IPLA: 1% lidocaine (5 mL) 12 Base VAS
Skriapas, 201141 RCT PNB (73);PNB + IRLA (74)
PNB: 2% lidocaine (5 mL)
IRLA: 2% lidocaine gel (10 mL) 12 NA VAS
Song, 200642 RCT P (30); PNB (30);IRLA (30)
PNB: 2% lidocaine (5 mL)
IRLA: 2% lidocaine gel (10 mL) 10 Base VAS
Szlauer, 200843 RCT PNB (25);PNB + IRLA (25)
PNB: 2% lidocaine (10 mL)
IRLA: 2% lidocaine gel (10 mL) 10 Base VAS
Trucchi, 200544 RCT PNB (20); IRLA (20) PNB: 2% lidocaine (10 mL)IRLA: 2% lidocaine gel (10 mL) 10 Base VAS
Turgut, 200650 RCT PNB (31); IVS (31) PNB: 2% lidocaine (10 mL)IVS: midazolam (0.07–0.1 mg/kg) 12 Base VAS
Vanni, 200445 RCT P (20); PNB (20) PNB: 2% lidocaine (10 mL) 10–12 Base VAS
Wang, 201646 RCT PNB + IRLA (95);SPA (92)
PNB: 1% lidocaine + 0.5% 
ropivacaine (5mL)
IRLA: 0.3% oxybuprocaine gel 
(10 mL)
SPA: 1.2% lidocaine (20mL)
12 Base VAS
Wu, 200147 RCT P (19); PPB (21) PPB: 1% lidocaine (5mL) 12 VAS
Yun, 200748 RCT PNB (113);PNB + IRLA (90)
PNB: 1% lidocaine (8mL)
IRLA: 2% lidocaine gel (10 mL) 12 Base VAS
Yurdakul, 200949 RCT IRLA (25);PNB + IRLA (50)
PNB: 0.25% ropivacaine (5 mL)
IRLA: 2% lidocaine gel (10 mL) 10 Base VAS
Table 1. Characteristics of included studies. IPLA: intraprostatic local anesthesia, IRLA: intrarectal local 
anesthesia, IVS: intravenous sedation PNB: periprostatic nerve block, P: placebo, PPB: pelvic plexus block, 
RCT: randomized controlled trial, SPA: spinal anesthesia, VAS: visual analog scale.
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confirmed these findings (Fig. 5). The rankings of the local anesthetic methods are similarly presented in Fig. 6. 
PNB + IVS and SPA were ranked first and the second, respectively, followed by PPB + IRLA, PNB + IPLA, PPB, 
PNB + IRLA, IVS, PNB, IPLA, and IRLA. There were 15 node-splitting models. With the exception of two models 
Figure 2. (A) Forest plots comparing IRLA with placebo, (B) Forest plots comparing PNB with IRLA, (C) 
Forest plots comparing PNB with Placebo, (D) Forest plots comparing PNB + IPLA with PNB, (E) Forest 
plots comparing PNB + IRLA with IRLA, (F) Forest plots comparing PNB + IRLA with PNB, (G) Forest 
plots comparing PPB + IRLA with PNB + IRLA, (H) Forest plots comparing SPA with PNB + IRLA IPLA: 
intraprostatic local anesthesia, IRLA: intrarectal local anesthesia, PNB: periprostatic nerve block, PPB: pelvic 
plexus block, SPA: spinal anesthesia.
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(PNB vs. PPB and PPB vs. placebo), 95% CrIs of inconsistency factors included zero and P-values of > 0.05 for the 
comparison between direct and indirect effects in all other node-splitting models.
There were 15 node-splitting models. With the exception of two models (PNB vs. PPB and PPB vs. placebo), 
95% CrIs of inconsistency factors included zero and P-values of > 0.05 for the comparison between direct and 
indirect effects in all other node-splitting models. There were no significant inconsistencies in results in this 
analysis.
Quality assessment and qualitative risk of bias. The risk of bias graph and assessment are summarized 
in Figs 7 and 8. There are three main sources of bias in the included trials. The first is insufficient number of 
participants in some trials, which may make it difficult to demonstrate the effect of local anesthesia. The second 
is that the number of biopsies taken was not identical for every patient in the trials. This variable may also affect 
the VAS score.
Figure 3. Network plot of evidence of all trials. The width of the lines is proportional to the number of trials 
comparing every pair of treatments, and the size of every node is proportional to the number of randomized 
participants. IPLA: intraprostatic local anesthesia, IRLA: intrarectal local anesthesia, IVS: intravenous sedation, 
PNB: periprostatic nerve block, PPB: pelvic plexus block, SPA: spinal anesthesia.
Figure 4. Relative effect table of local anesthetic method’s efficacy for pain control related prostate biopsy. 
Comparisons between treatments should be read from left to right, and the estimate is in the cell in common 
between the column-defining treatment and the row-defining treatment. For efficacy in local anesthesia, mean 
differences (MDs) less than 0 favor the column-defining treatment. Bold indicates statistical significance. IPLA: 
intraprostatic local anesthesia, IRLA: intrarectal local anesthesia, IVS: intravenous sedation, PNB: periprostatic 
nerve block, PPB: pelvic plexus block, SPA: spinal anesthesia.
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The results of GRADE quality assessment of direct evidence of each pairwise treatment comparison are shown 
in Table 2. Of the eight comparisons, certainty was low in six and very low in two.
Discussion
PCa is the most frequently diagnosed cancer worldwide in men, with approximately 1.1 million new cases being 
diagnosed each year51. Assuming that the current PBx standard of using 10–14 biopsy cores detects prostate 
cancer in up to 44% of patients52, then PBx can be expected to be performed in approximately 2.5 million cases 
a year worldwide. Recently, various types of local anesthetic methods have been proposed to reduce the discom-
fort and pain associated with PBx22. Consequently, there is ongoing research to identify the perfect method for 
reduction of pain. Therefore, we performed a systematic review and network meta-analysis of RCTs published to 
date to determine the most effective anesthetic methods for pain control. Although similar meta-analyses6,7,53–56 
have been performed previously, a new analysis was needed to incorporate the results of new trials that have been 
published on this topic. Moreover, previous meta-analyses only made direct comparisons, whereas we included 
Figure 5. Relative effect plot of local anesthetic method’s efficacy for pain control related prostate biopsy IPLA: 
intraprostatic local anesthesia, IRLA: intrarectal local anesthesia, IVS: intravenous sedation, PNB: periprostatic 
nerve block, PPB: pelvic plexus block, SPA: spinal anesthesia.
Figure 6. Rank probabilities plot for local anesthesia network of efficacy for pain control related prostate 
biopsy IPLA: intraprostatic local anesthesia, IRLA: intrarectal local anesthesia, IVS: intravenous sedation, PNB: 
periprostatic nerve block, PPB: pelvic plexus block, SPA: spinal anesthesia.
Figure 7. Risk of bias graph.
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multiple comparisons with more local anesthetic techniques (specifically, IVS, SPA, and PPB). Our study was an 
arm-based network meta-analysis with 11 arms (IPLA, IRLA, IVS, PNB, PPB, SPA, PNB + IPLA, PNB + IRLA, 
PNB + IVS, PPB + IRLA, and placebo).
Figure 8. Risk of bias assessment. Green plus: low risk of bias, Yellow question: unclear risk of bias, Red minus: 
high risk of bias.
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The most commonly used local anesthetic methods for PBx are IRLA and PNB. National Comprehensive 
Cancer Network guidelines state that local lidocaine injection is more efficacious in reducing pain during probe 
insertion, whereas PNB reduces pain during the biopsy itself57. European Urological Association guidelines rec-
ommend PNB as the standard of care58. IRLA is a convenient local anesthesia method that causes only a little 
discomfort to patients54. The most commonly used agent is lidocaine alone or in combination with other mole-
cules (prilocaine, nifedipine, dimethyl sulfoxide, etc.)59. Our results show that IRLA with lidocaine gel alone or 
in combination with other molecules could not significantly reduce the pain during the PBx, which is consistent 
with results from previous meta-analyses7,53,54. IRLA alone was the worst ranked method in this analysis other 
than placebo. Nash et al. were the first to describe the use of PNB before PBx in 19968. Subsequently, many tri-
als2,9,12,21,22,25,28,30,34,36,37,40,42 and meta-analyses7,54,55 have suggested that injection of local anesthetic around the 
nerve bundles might provide the best pain control during PBx. The results of our study also show that PNB 
significantly reduced pain compared with IRLA and placebo and are consistent with results from previous 
Certainty assessment
Number of 
patients Effect
Certainty Importance
Number 
of studies Study design
Risk of 
bias Inconsistency Indirectness Imprecision
Other 
considerations
The 
former
The 
latter
Absolute 
(95% CI)
1. IRLA vs Placebo
8 randomized trials seriousa not serious not serious seriousb none 571 489
MD 0.32 
lower
(0.72 lower 
to 0.09 
higher)
●●○○
LOW CRITICAL
2. PNB vs IRLA
14 randomized trials seriousa seriousc not serious not serious
publication 
bias strongly 
suspectedd
724 718
MD 1.61 
lower
(2.08 lower 
to 1.15 
lower)
●○○
VERY 
LOW
CRITICAL
3. PNB vs Placebo
10 randomized trials seriousa seriousc not serious not serious none 457 422
MD 2.04 
lower
(2.77 lower 
to 1.31 
lower)
●●○○
LOW CRITICAL
4. PNB + IPLA vs PNB
5 randomized trials seriousa seriousc not serious not serious none 359 345
MD 0.97 
lower
(1.33 lower 
to 0.6 
lower)
●●○○
LOW CRITICAL
5. PNB + IRLA vs IRLA
4 randomized trials seriousa seriousc not serious not serious none 169 168
MD 1.75 
lower
(2.97 lower 
to 0.53 
lower)
●●○○
LOW IMPORTANT
6. PNB + IRLA vs PNB
7 randomized trials seriousa seriousc not serious not serious none 423 447
MD 0.61 
lower
(1.09 lower 
to 0.13 
lower)
●●○○
LOW IMPORTANT
7. PPB + IRLA vs PNB + IRLA
2 randomized trials seriousa not serious not serious seriouse none 137 136
MD 1.09 
lower
(1.29 lower 
to 0.9 
lower)
●●○○
LOW IMPORTANT
8. SPA vs PNB + IRLA
3 randomized trials seriousa seriousc not serious seriouse none 177 181
MD 1.47 
lower
(2.73 lower 
to 0.21 
lower)
●○○○
VERY 
LOW
IMPORTANT
Table 2. GRADE quality assessment of direct evidence of each pairwise treatment comparison. CI: confidence 
interval, IPLA: intraprostatic local anesthesia, IRLA: intrarectal local anesthesia, PNB: periprostatic nerve 
block, PPB: pelvic plexus block, MD: mean difference, SPA: spinal anesthesia Explanations. aThe risk of bias 
is most of unclear domains. bThe upper and lower limits of 95% CI include both meaningful benefit and harm. 
cSignificant heterogeneity observed. dFunnel plot show significant asymmetry. Egger’s tests were less than 0.05 
(P = 0.0002). eTotal number of participants is small.
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meta-analyses7,54–56. However, PNB alone had a probability of being ranked just seventh in effectiveness in the 
current study.
Combining PNB with IPLA or with IRLA results in a more extensive pain control effect53. In 2005, Mutaguchi 
et al.60 reported IPLA was a new local anesthesia technique for anesthetizing the prostate by blocking all sen-
sory nerves from the posterior and anterior. Our results show that PNB with either IPLA or IRLA significantly 
reduced pain compared with placebo and had intermediate probability of being ranked fourth and sixth, respec-
tively. However, IPLA alone did not significantly reduce the pain during the PBx. Recently, IPLA was shown to 
extend the time of PBx, but also provide improved pain control compared to PNB59. Nonetheless, more RCTs are 
required to justify the single use of IPLA in general.
Three recent trials investigated the effect of IVS for pain control during PBx14,31,50. Atta et al.14 conducted IVS 
by slow infiltration (3–5 min) of diazepam (5 mg) just before probe insertion and found that this IVS approach 
significantly decreases discomfort and fear of insertion of the probe and alleviates patient anxiety. In addition, 
PNB + IVS displays a significantly lower VAS score during PBx. Mazdak et al.31 performed IVS by infiltration of 
midazolam (25 μg/kg), fentanyl (2 μg/kg), and ketamine (1 mg/kg) through an antecubital vein at 5 min before 
taking the biopsies. They reported that the differences in VAS score between PNB + IRLA and IVS are not statis-
tically significant. Additionally, they reported SPA significantly reduces pain compared with IVS. Turgut et al.50  
injected midazolam (0.07–0.1 mg/kg) intravenously 5–10 min before the procedure. They showed that IVS 
displays a significantly lower VAS score compared with placebo, whereas no significant difference is observed 
between IVS and PNB. Our results show that IVS alone had no pain control effects compared with PNB alone, 
whereas combined PNB + IVS significantly reduced pain compared with PNB + IRLA. PNB + IVS had the high-
est probability of being ranked first. Nevertheless, IVS has a risk of respiratory and cardiovascular depression, and 
the use of anesthetic staff has cost implications50. Only three trials were analyzed in the aforementioned studies, 
so more RCTs should be performed for more accurate analysis of the effect of IVS.
PPB is also used to control biopsy pain. Wu et al.47 first described PPB using 5 mL of 1% lidocaine directly 
lateral to the tip of the seminal vesicles under grey-scale ultrasonography guidance. They found that this method 
does not reduce biopsy-related pain. Conversely, Akpinar et al.10 conducted a trial comparing PPB (using 2 mL 
of 2% lidocaine), to PNB at the same dosage and concentration. The authors reported that PPB provides superior 
analgesia to PNB because it acts on the prostate proximally. They suggested that the reasons for their divergent 
results are not clear but may be caused by the use of Doppler ultrasonography and larger cohorts unlike the study 
of Wu et al.47. Color Doppler ultrasonography is helpful for identifying the entire pelvic plexus with no influence 
of the left lateral decubitus position59. Another two studies reported that PPB + IRLA has significantly more 
effective pain control than PNB + IRLA17,24. Although the currently available guidelines do not mention the use 
of PPB, our study suggests the possibility that PPB might be superior to PNB. This concept requires more RCTs 
to confirm this possibility. Moreover, this procedure should be conducted only by skilled practitioners under the 
guidance of color Doppler ultrasonography, a requirement that may represent a limitation for this method.
SPA is an ideal anesthetic for anorectal surgery1 and had a highly probability of being ranked second in our 
study. Four of the included trials investigated the PBx pain control effect of SPA1,31,34,46. We classified the caudal 
block in one trial46 into one kind of SPA in which caudal block was accomplished using 20 mL of 1.2% lidocaine. 
Other trials used SPA with a low dose of 0.5% bupivacaine (0.5–1.5 mL) at the L3-5 level. They reported SPA sig-
nificantly decreases pain during the procedure1,31,34,46. Moreover, there was no significant difference in anesthesia 
time or pain due to anesthesia itself compared with PNB. Nonetheless, SPA requires the presence of an anesthe-
siologist, which adds to the overall cost of the procedure and reduces the likelihood of SPA being practiced in an 
outpatient setting. Other drawbacks to SPA include a potential to cause a spinal headache or backache, systemic 
blood pressure or heart rate changes, and risk of infection into the subarachnoid space1.
To the best of our knowledge, ours is the first network meta-analysis to evaluate the optimal local anesthetic 
for controlling PBx-related pain in order to help clinicians select an appropriate anesthetic method for patients 
undergoing PBx. Our meta-analysis results suggest that various local anesthetic modalities, alone or in combina-
tion, were significantly more effective than placebo in alleviating pain for TRUS-guided PBx. Of these methods, 
PNB + IVS and SPA seem to be the most effective way to control PBx-related pain. However, several medical and 
socioeconomic factors should be considered because SPA and IVS are undoubtedly associated with increases of 
medical cost, need for anesthesiologist, need for extra medical personnel for monitoring patients’ recovery, longer 
hospital stay, and additional risk of morbidities, etc. In the current outpatient setting, PPB + IRLA, PNB + IPLA, 
PPB, PNB + IRLA, and PNB are acceptable modalities, but it is still uncertain whether PPB can be superior to 
PNB. Using the results of this study, clinicians could select the most effective method by providing a choice of 
anesthetic methods and discussing the methods with patients based on the patient’s personality, medical condi-
tion, and financial status, and the capabilities of the hospital.
We performed only the GRADE assessment of the direct comparison without assessing of indirect evidences. 
However, there are the GRADE Working Group approach for accessing the quality of treatment effect estimates 
from network meta-analysis61. Salanti et al. also suggested an approach to determining confidence in the output of 
a network meta-analysis62. They have emphasized the importance of assessing the quality and confidence of each 
pairwise comparison (containing direct, indirect or mixed evidence) and the ranking estimates. The judgments 
of the evidence of the network meta-analysis may differ from those of the evidence of the pairwise meta-analysis. 
Since most of the risk of bias for included studies was unclear, all of the GRADE risk-of-bias items were assessed 
as serious. This resulted in low and very low quality of all evidence due to the low quality of the studies included. 
Low level of GRADE assessment means that further research is highly likely to have a significant impact on our 
confidence in estimating effects and changes in estimates. Very low of GRADE assessment means that estimates 
of effects are highly uncertain. There was a discrepancy in the placebo arm among the included studies. For exam-
ples, some trials3,23,32,35 performed periprostatic saline injection, but others5,9,18,19,29,37 instilled placebo solutions 
into the rectum. Moreover, there was also no agreement in the type or dose of anesthetic in the same group. A 
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major practical disadvantage of the VAS is that subsequent distance measurements are required63. Patients have 
difficulty finding the point that best describes the pain they feel. In other words, the VAS can be measured higher 
than actually talking about pain in words64,65. It may be easy to interpret the category of modest VAS meaning-
fully. Although VAS is may useful for the comparison of pain between the two groups, the interpretation of a 
single VAS may be subjective63. Network meta-analysis assumes that some treatment arms can be grouped in 
a similarity of rationality and procedure. Although there is added potential for combining studies that are not 
adequately similar, this assumption allows us to group treatment arms together as one node in the network66. 
Further high-quality RCTs are needed to overcome these drawbacks, to validate this result, and to find the opti-
mal anesthetic method for PBx.
In conclusion, our meta-analysis suggests that various local anesthetic method, alone or in combination, were 
more effective in alleviating pain for TRUS-guided PBx than placebo. Of these anesthetic methods, PNB + IVS 
and SPA seem to be the most effective way to control PBx-related pain. Unfortunately, increase of medical cost 
and additional risk of morbidity must be considered before using these methods. In the current outpatient setting, 
PPB + IRLA, PNB + IPLA, PPB, PNB + IRLA, and PNB are the more acceptable options. Although the currently 
available guidelines do not mention the use of PPB, our study suggests that PPB might be a promising alternative 
to PNB. Further high-quality RCTs are needed to validate these results and clarify the optimal anesthetic method.
Material and Method
This systematic review was registered in PROSPERO (CRD42018092602).
Literature search. We performed literature searches on PubMed/Medline, Embase, Cochrane Library, 
Web of science, Scopus, and Clinical Key up to March 2018. Only published trials in English were included. 
Conference and meeting abstracts were excluded even if they met the eligibility criteria. The search terms used 
included ‘transrectal’, ‘prostate’, ‘biopsy’, ‘intraprostatic’, ‘periprostatic’, ‘intrarectal’, ‘spinal’, ‘anesthesia’, ‘block’, ‘pel-
vic plexus’, and relevant variants. A total of 1842 possible articles, of which 982 articles remained after remov-
ing duplicates, were found using these literature searches. Two authors (DKK and YSH) reviewed the titles and 
abstracts in consideration of the inclusion criteria and reviewed the independently identified papers. In cases of 
disagreement, the reviewers decided by agreement on whether or not to include the article.
Trial inclusion criteria and exclusion criteria. The eligibility of a study was evaluated by the PICOS 
(participants, interventions, comparators, outcomes, and study design) approach and the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses guidelines67. Study population was defined as patients who 
underwent TRUS-guided PBx, and intervention was defined as local anesthesia. The comparator was defined as 
placebo or anesthetic method. The outcomes were biopsy pain scores that were measured using a visual analogue 
scale (VAS). Inclusion criteria were as follows: (1) RCT, (2) human research, (3) patients underwent TRUS-guided 
PBx, (4) use of local anesthesia, and (5) reported outcome values (VAS: mean and standard deviation could be 
calculated).
Data extraction. Two independent authors (DKK and YSH) extracted the data using a predesigned form. 
Any conflicts in extracted data between the two authors were resolved via consensus. Extracted data included the 
first author, publication year, study design, treatment arms, number of patients, local anesthetic method and anes-
thetics, inclusion and exclusion criteria, number of PBx core, type of pain scale, and outcome. The main outcome 
was the biopsy pain score measured by VAS.
Study quality assessments and quality of evidence. The risk of bias was evaluated in individual stud-
ies using tools recommended in recent meta-analysis guidelines that rate various aspects of RCT design and 
implementation68. Risk of bias was assessed for random sequence generation, allocation concealment, blinding 
of participants and researchers, blinding of outcome assessment, incomplete outcome data, selective reporting, 
and others.
The Grading of Recommendations, Assessments, Developments, and Evaluation (GRADE) was used to 
provide a systematic approach to the evaluation of the quality of evidence and strength of recommendations69. 
Criteria for consideration included assessment of methodology, precision and consistency of results, directness, 
and risk of publication bias. Based on five criteria, we assessed only direct evidence of pairwise meta-analysis by 
classifying the quality of evidence as one of four levels (i.e., high, moderate, low, and very low).
Statistical analysis. A pairwise meta-analysis was performed on the comparison of a minimum of two stud-
ies. Outcomes are reported as a combination of the weighted mean difference (MD) with 95% confidence interval 
(CI) and the P-value. The pooled MD with 95% CIs expresses the difference in the size of the intervention effect. 
Statistical heterogeneity between trials was evaluated by Chi-square heterogeneity tests. The I2 statistic was also 
calculated to measure discrepancies between clinical trials. Either a P-value of < 0.05 for the Cochran Q statistic 
or an I2 statistic of > 50% indicated significant heterogeneity between trials68.
To indirectly compare the effect of each local anesthetic method on the endpoint (VAS), we conducted a 
network meta-analysis using a Bayesian hierarchical random effects model for continuous outcomes. This model 
estimates treatment-specific effects and effect differences. Pooled estimates were obtained using the Markov 
Chains Monte Carlo method in which each chain has 20,000 simulations and the first 5,000 simulations are 
discarded as burn-in. We modeled the continuous outcomes for every local anesthetic method of all trials and 
quantified the association between MDs with 95% credible intervals (CrIs) among studies (CrIs can be regarded 
as similar to conventional CIs). The selection of a random effects model for reported outcomes was based on the 
deviance information criteria. The random effects model is a measure of model fit that penalizes model com-
plexity70. The node-splitting method was applied for computing the inconsistency of the model. The results of 
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node-splitting analysis are considered to show no significant inconsistency when 95% CIs of inconsistency fac-
tors include zero or when there is a large probability value (P-value > 0.05) for the comparison between direct 
and indirect effects71. The relative effects were also assessed visually using the relative effects table and plots. 
Probability values were summarized and are reported as a rank probabilities table and plot.
We conducted the pairwise meta-analysis using Review Manager v.5.1 (The Nordic Cochrane Center, The 
Cochrane Collaboration, Copenhagen, Denmark, 2008). The network meta-analyses were conducted using R 
3.4.3 (R development Core Team, Vienna, http://www.R-project.org) with the ‘GEMTC’ packages.
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